In late 2025, Jan Janisch-Hanzlik faced a stark turning point. At 49, the former nurse saw her multiple sclerosis steal her mobility, end her career, and force her to prepare for a life limited by a wheelchair. Standard treatments failed to slow the disease’s progression, leaving her with few options. Then, a clinical trial at the University of Nebraska Medical Center offered a radical alternative: CAR T cell therapy, a technology originally engineered to fight cancer, now repurposed to target the body’s own immune system when it turns against itself.
Janisch-Hanzlik became the first patient in the trial, enrolling after persistent inquiries to the clinic. Her story reflects a growing shift in medical research, where therapies developed for oncology are being adapted to tackle autoimmune disorders such as lupus, vasculitis, and Graves’ disease. The core idea is to reprogram immune cells to eliminate rogue cells that mistakenly attack healthy tissue, effectively resetting the immune system to a pre-disease state.
The science behind CAR T: from cancer fighter to immune reset
CAR T cell therapy, short for chimeric antigen receptor T-cell therapy, was first approved in 2017 for certain blood cancers. The approach involves extracting a patient’s T cells, engineering them in a lab to express receptors that recognize and destroy specific cells, then reinfusing them into the patient. In oncology, these receptors are designed to hunt down cancer cells. Researchers now believe the same precision can be redirected to identify and eliminate autoimmune cells without suppressing the entire immune system.
Clinical trials across the U.S. and Europe are testing CAR T in autoimmune diseases, with hundreds of studies registered on ClinicalTrials.gov. Early results suggest the therapy can induce remission in patients unresponsive to conventional treatments. For example, patients with multiple sclerosis have shown significant reductions in disease activity on MRI scans after receiving CAR T. While long-term data is still limited, the initial signals are promising enough to warrant cautious optimism.
Who stands to benefit from CAR T in autoimmune care?
CAR T is not a one-size-fits-all solution, but it offers new hope for patients with severe, treatment-resistant autoimmune conditions. Conditions currently under investigation include:
- Multiple sclerosis (MS): A neurodegenerative disease where the immune system attacks the protective sheath around nerves. CAR T aims to remove the rogue immune cells driving the attack.
- Lupus (Systemic Lupus Erythematosus): An inflammatory disease where the body’s immune system attacks its own tissues and organs. Early trials report symptom remission in some patients.
- Vasculitis: A group of disorders characterized by inflammation of blood vessels. CAR T may help reduce vascular damage by targeting the underlying immune dysfunction.
- Graves’ disease: An autoimmune condition affecting the thyroid, leading to hyperthyroidism. Researchers are exploring whether CAR T can induce long-term remission.
The eligibility criteria for these trials are strict. Patients must have failed multiple standard therapies, and their conditions must be severe enough to justify the risks associated with CAR T, including cytokine release syndrome and potential long-term immune suppression. Still, for those who qualify, the potential rewards outweigh the risks.
What’s next for CAR T in autoimmune disease?
As research accelerates, the medical community is closely watching the evolution of CAR T therapy beyond oncology. Regulatory agencies are evaluating data from early trials, and larger studies are being planned to confirm safety and efficacy. If results continue to be positive, CAR T could transition from experimental treatment to a standard option for certain autoimmune diseases within the next five years.
For patients like Jan Janisch-Hanzlik, this shift cannot come soon enough. Her participation in the trial was not just a personal milestone—it was a step toward validating a new frontier in medicine. While challenges remain, the early success stories underscore the transformative potential of repurposing cancer therapies for autoimmune care. The next decade may well redefine how autoimmune diseases are treated, turning what was once considered incurable into a manageable condition.
AI summary
CAR-T hücresi tedavisi, kanser için geliştirildi ancak artık multipl skleroz ve lupus gibi otoimmün hastalıklarda da umut vaat ediyor. Peki nasıl çalışıyor ve ne kadar güvenilir?
